Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer

類似資料

• PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane–Based Neoadjuvant Chemotherapy
  著者:: Guo, Sanxing, 等
  出版事項: (2020)
• Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes
  著者:: Darb-Esfahani, Silvia, 等
  出版事項: (2014)
• Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy
  著者:: Darb-Esfahani, Silvia, 等
  出版事項: (2016)
• Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy
  著者:: Darb-Esfahani, Silvia, 等
  出版事項: (2009)
• An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas
  著者:: Noske, Aurelia, 等
  出版事項: (2011)